A Global, Open-Label, Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Lay Description
Category
- Heart, Vascular and Blood
- Lungs, Breathing and Bronchial
- IRB Number
- 20190423HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Johnnie Jones
210-450-7277
jonesj21@uthscsa.edu
Principal Investigator
Rodolfo Estrada Anzueto